series-c-plus
Stage
2010
Founded
3
Investors
About
NOXXON Pharma is a clinical-stage biotechnology company developing therapies that modulate the tumor microenvironment by targeting the chemokine CXCL12/SDF-1. Its lead program, olaptesed pegol (NOX‑A12), is an L‑RNA aptamer designed to enhance anti-tumor immune responses and improve the activity of combination cancer treatments.
Explore NOXXON Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.